PMID: 7915256Mar 1, 1994Paper

Phase I/II vaccination study of recombinant peptide F46 corresponding to the HIV-1 transmembrane protein coupled with 2.4 dinitrophenyl (DNP) Ficoll

Infection
S SchwanderM Dietrich

Abstract

In order to evaluate tolerance, toxicity, and in vivo antigenicity, 29 HIV-1-infected patients (eight with ARC and 21 with AIDS) were vaccinated with a synthetic peptide derived from the gp41 transmembrane protein of the HIV-1. This peptide had been coupled with 2.4 dinitrophenyl-Ficoll (F46), a T-cell independent adjuvant. The patients received a single intradeltoid injection of either 0.1 or 0.3 mg of F46. Five of the individuals with AIDS were boostered, four of them twice. Anti-F46 antibody titers were measured before vaccination, and on days 7, 14, 21, 28, 90, 180 and 270 after vaccination. Anti-F46 titers rose at least twofold over prestudy values in 10/21 individuals with AIDS and in 1/8 individuals with ARC at least once during the observation period. The overall response, however, consisted of only weak antibody production that was independent of the dose or patient characteristics. No signs of toxicity or of clinical progression related to the vaccination were observed in this phase I/II trial of a T-cell independent therapeutic vaccine.

References

Apr 15, 1991·Annals of Internal Medicine·A S FauciG Pantaleo
Jan 1, 1991·Advances in Experimental Medicine and Biology·B S Stein, E G Engleman
Feb 1, 1988·AIDS·E K ThomasR A Weiss
Jan 1, 1985·International Archives of Allergy and Applied Immunology·K DrösslerJ L Turk
Nov 1, 1985·Annals of Internal Medicine·D L BowenA S Fauci
Nov 4, 1993·The New England Journal of Medicine·N L Letvin

❮ Previous
Next ❯

Citations

Jul 20, 2005·Expert Review of Vaccines·Aldar S Bourinbaiar, Rivka Abulafia-Lapid
Jan 31, 2002·HIV Clinical Trials·Vichai Jirathitikal, Aldar S Bourinbaiar
Aug 30, 2005·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Orapun MetadilogkulAldar S Bourinbaiar
May 22, 2003·Dermatologic Clinics·Mathijs H BrentjensStephen K Tyring
Nov 27, 2015·The Journal of Immunology : Official Journal of the American Association of Immunologists·Melissa A KachuraJohn D Campbell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.